{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T14:17:57Z","timestamp":1781360277812,"version":"3.54.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,30]]},"DOI":"10.7759\/cureus.72721","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T19:35:46Z","timestamp":1730316946000},"source":"Crossref","is-referenced-by-count":1,"title":["Regorafenib-Triggered Hemophagocytic Lymphohistiocytosis: A Report of Two Cases"],"prefix":"10.7759","author":[{"given":"Ilfad","family":"Blazevic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadim","family":"Fares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blandine","family":"Delaunay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Gomez-Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2012.684752","article-title":"Regorafenib for cancer","volume":"21","author":"Strumberg D","year":"2012","unstructured":"Strumberg D, Schultheis B. Regorafenib for cancer. Expert Opin Investig Drugs. 2012, 21:879-89. 10.1517\/13543784.2012.684752","journal-title":"Expert Opin Investig Drugs"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.101912","article-title":"Molecular insight of regorafenib treatment for colorectal cancer","volume":"81","author":"Arai H","year":"2019","unstructured":"Arai H, Battaglin F, Wang J, Lo JH, Soni S, Zhang W, Lenz HJ. Molecular insight of regorafenib treatment for colorectal cancer. Cancer Treat Rev. 2019, 81:101912. 10.1016\/j.ctrv.2019.101912","journal-title":"Cancer Treat Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13181","article-title":"Novel approaches for molecular targeted therapy against hepatocellular carcinoma","volume":"48","author":"Eso Y","year":"2018","unstructured":"Eso Y, Marusawa H. Novel approaches for molecular targeted therapy against hepatocellular carcinoma. Hepatol Res. 2018, 48:597-607. 10.1111\/hepr.13181","journal-title":"Hepatol Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx376.060","article-title":"Immunomodulation by regorafenib alone and in combination with anti PD1 antibody on murine models of colorectal cancer","volume":"28","author":"Hoff S","year":"2017","unstructured":"Hoff S, Gr\u00fcnewald S, R\u00f6se L, Zopf D. Immunomodulation by regorafenib alone and in combination with anti PD1 antibody on murine models of colorectal cancer. Ann Oncol. 2017, 28:423. 10.1093\/annonc\/mdx376.060","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001657","article-title":"Regorafenib enhances antitumor immunity via inhibition of p38 kinase\/Creb1\/Klf4 axis in tumor-associated macrophages","volume":"9","author":"Ou DL","year":"2021","unstructured":"Ou DL, Chen CW, Hsu CL, et al.. Regorafenib enhances antitumor immunity via inhibition of p38 kinase\/Creb1\/Klf4 axis in tumor-associated macrophages. J Immunother Cancer. 2021, 9:10.1136\/jitc-2020-001657","journal-title":"J Immunother Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3416","article-title":"Regorafenib-avelumab combination in patients with microsatellite stable colorectal cancer (REGOMUNE): a single-arm, open-label, phase II trial","volume":"27","author":"Cousin S","year":"2021","unstructured":"Cousin S, Cantarel C, Guegan JP, et al.. Regorafenib-avelumab combination in patients with microsatellite stable colorectal cancer (REGOMUNE): a single-arm, open-label, phase II trial. Clin Cancer Res. 2021, 27:2139-47. 10.1158\/1078-0432.CCR-20-3416","journal-title":"Clin Cancer Res"},{"key":"ref7","unstructured":"A phase I\/\u200bII study of regorafenib plus avelumab in solid tumors (REGOMUNE). (2023). Accessed. September 21, 2024: https:\/\/clinicaltrials.gov\/study\/NCT03475953."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka S","year":"2020","unstructured":"Fukuoka S, Hara H, Takahashi N, et al.. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase ib trial (REGONIVO, EPOC1603). J Clin Oncol. 2020, 38:2053-61. 10.1200\/JCO.19.03296","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S46255","article-title":"Hemophagocytic lymphohistiocytosis: review of etiologies and management","volume":"5","author":"George MR","year":"2014","unstructured":"George MR. Hemophagocytic lymphohistiocytosis: review of etiologies and management. J Blood Med. 2014, 5:69-86. 10.2147\/JBM.S46255","journal-title":"J Blood Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13602","article-title":"Analysis of the clinical characteristics of lamotrigine-induced haemophagocytic lymphohistiocytosis","volume":"47","author":"Wang C","year":"2022","unstructured":"Wang C, Fan Z, He Y, Fang W, Sun W, Li Z. Analysis of the clinical characteristics of lamotrigine-induced haemophagocytic lymphohistiocytosis. J Clin Pharm Ther. 2022, 47:745-51. 10.1111\/jcpt.13602","journal-title":"J Clin Pharm Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2023.03.014","article-title":"Carbamazepine-Triggered Hemophagocytic Lymphohistiocytosis: A Case Report and Review of Literature","volume":"144","author":"Kaur P","year":"2023","unstructured":"Kaur P, Munikoty V, Chandramohan V. Carbamazepine-Triggered Hemophagocytic Lymphohistiocytosis: A Case Report and Review of Literature. Pediatr Neurol. 2023, 144:69-71. 10.1016\/j.pediatrneurol.2023.03.014","journal-title":"Pediatr Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000690","article-title":"Hemophagocytic lymphohistiocytosis in advanced melanoma treated with dabrafenib and trametinib combination: two cases","volume":"30","author":"Samaran Q","year":"2020","unstructured":"Samaran Q, Belakebi D, Theret S, et al.. Hemophagocytic lymphohistiocytosis in advanced melanoma treated with dabrafenib and trametinib combination: two cases. Melanoma Res. 2020, 30:519-23. 10.1097\/CMR.0000000000000690","journal-title":"Melanoma Res"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.26502\/acmcr.96550332","article-title":"A case of hemophagocytic lymphohistiocytosis induced by regorafenib","volume":"5","author":"Jaffrelot M","year":"2021","unstructured":"Jaffrelot M, Gadaud N, Delord J-P, Gomez-Roca C, B\u00e9trian S. A case of hemophagocytic lymphohistiocytosis induced by regorafenib. Arch Clin Med Case Rep. 2021, 5:96-100.","journal-title":"Arch Clin Med Case Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet L","year":"2014","unstructured":"Fardet L, Galicier L, Lambotte O, et al.. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014, 66:2613-20. 10.1002\/art.38690","journal-title":"Arthritis Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2018-105485","article-title":"Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the PRF1A91V gene polymorphism","volume":"56","author":"Al-Samkari H","year":"2019","unstructured":"Al-Samkari H, Snyder GD, Nikiforow S, Tolaney SM, Freedman RA, Losman JA. Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the PRF1A91V gene polymorphism. J Med Genet. 2019, 56:39-42. 10.1136\/jmedgenet-2018-105485","journal-title":"J Med Genet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.06.048","article-title":"Genetic predisposition to hemophagocytic lymphohistiocytosis: report on 500 patients from the Italian registry","volume":"137","author":"Cetica V","year":"2016","unstructured":"Cetica V, Sieni E, Pende D, et al.. Genetic predisposition to hemophagocytic lymphohistiocytosis: report on 500 patients from the Italian registry. J Allergy Clin Immunol. 2016, 137:188-196.e4. 10.1016\/j.jaci.2015.06.048","journal-title":"J Allergy Clin Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/301361-regorafenib-triggered-hemophagocytic-lymphohistiocytosis-a-report-of-two-cases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T19:35:49Z","timestamp":1730316949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/301361-regorafenib-triggered-hemophagocytic-lymphohistiocytosis-a-report-of-two-cases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.72721","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,30]]}}}